Andrei Racila
About
Andrei Racila is a scholar working on Epidemiology, Hepatology and Surgery.
According to data from OpenAlex, Andrei Racila has authored 55 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Epidemiology, 37 papers in Hepatology and 7 papers in Surgery. Recurrent topics in Andrei Racila's work include Liver Disease Diagnosis and Treatment (45 papers), Liver Disease and Transplantation (23 papers) and Liver Diseases and Immunity (17 papers). Andrei Racila is often cited by papers focused on Liver Disease Diagnosis and Treatment (45 papers), Liver Disease and Transplantation (23 papers) and Liver Diseases and Immunity (17 papers). Andrei Racila collaborates with scholars based in United States, France and Germany. Andrei Racila's co-authors include Zobair M. Younossi, Maria Stepanova, Linda Henry, Issah Younossi, Sharon Hunt, Deirdre B Blissett, Youssef Younossi, Robert Blissett, Rachel Beckerman and Fatema Nader and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.
In The Last Decade
Andrei Racila
52 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrei Racila United States | 20 | 2.1k | 1.3k | 734 | 367 | 300 | 55 | 2.4k | ||
| Leyla de Avila United States | 16 | 2.0k 1.0× | 864 0.7× | 1.0k 1.4× | 381 1.0× | 330 1.1× | 36 | 2.5k | ||
| Issah Younossi United States | 21 | 1.9k 0.9× | 1.3k 1.1× | 618 0.8× | 324 0.9× | 263 0.9× | 45 | 2.2k | ||
| Stephen E. Congly Canada | 18 | 1.5k 0.7× | 749 0.6× | 504 0.7× | 364 1.0× | 201 0.7× | 60 | 2.0k | ||
| Alita Mishra United States | 25 | 2.6k 1.2× | 1.7k 1.3× | 790 1.1× | 523 1.4× | 451 1.5× | 42 | 3.1k | ||
| Marcelo Kugelmas United States | 18 | 1.8k 0.8× | 1.5k 1.2× | 441 0.6× | 587 1.6× | 343 1.1× | 47 | 2.6k | ||
| Cynthia Behling United States | 17 | 1.7k 0.8× | 714 0.6× | 819 1.1× | 389 1.1× | 115 0.4× | 27 | 2.2k | ||
| Darren Jun Hao Tan Singapore | 27 | 1.6k 0.7× | 954 0.8× | 550 0.7× | 399 1.1× | 313 1.0× | 99 | 2.4k | ||
| Fatema Nader United States | 29 | 3.4k 1.6× | 2.2k 1.7× | 1.3k 1.7× | 456 1.2× | 383 1.3× | 76 | 3.9k | ||
| Thomas G. Cotter United States | 18 | 1.2k 0.6× | 672 0.5× | 349 0.5× | 381 1.0× | 224 0.7× | 55 | 1.7k | ||
| Narendra S. Choudhary India | 25 | 1.8k 0.8× | 1.2k 1.0× | 697 0.9× | 1.0k 2.8× | 229 0.8× | 156 | 2.8k |
Countries citing papers authored by Andrei Racila
Since
Specialization
Citations
This map shows the geographic impact of Andrei Racila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrei Racila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrei Racila more than expected).
Fields of papers citing papers by Andrei Racila
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrei Racila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrei Racila. The network helps show where Andrei Racila may publish in the future.
Co-authorship network of co-authors of Andrei Racila
This figure shows the co-authorship network connecting the top 25 collaborators of Andrei Racila. A scholar is included among the top collaborators of Andrei Racila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrei Racila. Andrei Racila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Labriola, Dominic, et al.. (2026). Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis. Hepatology Communications. 10(3).
2.
Younossi, Zobair M., Sean Felix, Brian Lam, et al.. (2025). Serum Bile Acid Elevation is an Independently Associated With Pruritus in Patients With At-risk Metabolic Dysfunction-associated Steatotic Liver Disease. Journal of Clinical and Experimental Hepatology. 15(4). 102549–102549.
3.
Younossi, Z.M., Leyla de Avila, Andrei Racila, et al.. (2025). Prevalence and predictors of cirrhosis and portal hypertension in the United States. Hepatology. 82(5). 1229–1240.
4.
Yılmaz, Yusuf, et al.. (2025). Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry. Clinical and Translational Gastroenterology. 16(6). e00844–e00844.
5.
Younossi, Zobair M., Andrei Racila, Linda Henry, et al.. (2024). Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis. Hepatology. 81(4). 1318–1327.
6.
Younossi, Zobair M., Maria Stepanova, Issah Younossi, & Andrei Racila. (2024). Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH). JHEP Reports. 7(3). 101276–101276.
7.
Younossi, Zobair M., Maria Stepanova, Issah Younossi, & Andrei Racila. (2024). Validation of a Primary Biliary Cholangitis–Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC. Clinical and Translational Gastroenterology. 15(9). e1–e1.
8.
Younossi, Zobair M., Maria Stepanova, Sean Felix, et al.. (2023). The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 57(12). 1417–1422.
9.
Lam, Brian, Maria Stepanova, Chapy Venkatesan, et al.. (2022). Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system. PLoS ONE. 17(2). e0263417–e0263417.
10.
Younossi, Zobair M., Yusuf Yılmaz, Mohamed El‐Kassas, et al.. (2022). The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry. Hepatology Communications. 6(10). 2860–2866.
11.
Younossi, Zobair M., Naim Alkhouri, Fasiha Kanwal, et al.. (2022). A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 57(3). 304–312.
12.
Younossi, Zobair M., Maria Stepanova, Brian Lam, et al.. (2021). Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection. Hepatology Communications. 6(11). 3062–3072.
13.
Younossi, Zobair M., Andrei Racila, Andrew J. Muir, et al.. (2021). Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clinical Gastroenterology and Hepatology. 20(2). 438–446.
14.
Younossi, Zobair M., Maria Stepanova, Issah Younossi, & Andrei Racila. (2020). Development and validation of a hepatitis B‐specific health‐related quality‐of‐life instrument: CLDQ‐HBV. Journal of Viral Hepatitis. 28(3). 484–492.
15.
Younossi, Zobair M., Maria Stepanova, Janus P. Ong, et al.. (2020). Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clinical Gastroenterology and Hepatology. 19(3). 580–589.e5.
16.
Younossi, Zobair M., Radhika P. Tampi, Fatema Nader, et al.. (2019). Hypothetical treatment of patients with non‐alcoholic steatohepatitis: Potential impact on important clinical outcomes. Liver International. 40(2). 308–318.
17.
Younossi, Zobair M., Radhika P. Tampi, Andrei Racila, et al.. (2019). Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. Diabetes Care. 43(2). 283–289.
18.
Sayıner, Mehmet, Maria Stepanova, Leyla de Avila, et al.. (2019). Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Digestive Diseases and Sciences. 65(2). 416–422.
19.
Younossi, Zobair M., Maria Stepanova, K. Rajender Reddy, et al.. (2018). Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C. Liver International. 39(1). 54–59.
20.
Younossi, Zobair M., Maria Stepanova, Linda Henry, et al.. (2017). A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ ‐NAFLD . Liver International. 37(8). 1209–1218.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Leyla de Avila Breakdown of academic impact, for papers by Issah Younossi Breakdown of academic impact, for papers by Stephen E. Congly Breakdown of academic impact, for papers by Alita Mishra Breakdown of academic impact, for papers by Marcelo Kugelmas Breakdown of academic impact, for papers by Cynthia Behling Breakdown of academic impact, for papers by Darren Jun Hao Tan Breakdown of academic impact, for papers by Fatema Nader Breakdown of academic impact, for papers by Thomas G. Cotter Breakdown of academic impact, for papers by Narendra S. Choudhary